ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS

Remission Rates Double At Phase II

 
• By Ian Haydock
Leukemia
New Hope For HR-MDS Patients? • Source: Shutterstock

More from ASCO

More from Conferences